Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 25 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (7)
P 1 (4)
P 2 (4)
P 3 (2)

Trial Status

Completed11
Recruiting6
Enrolling By Invitation2
Not Yet Recruiting2
Unknown2
Withdrawn2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07539012Not ApplicableNot Yet RecruitingPrimary

Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy

NCT05795699Phase 3CompletedPrimary

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT07441616Not ApplicableNot Yet Recruiting

Partial Range Of Field IOLs in DMEK-Enabled Procedures

NCT04175938Phase 1WithdrawnPrimary

Assessment of Corneal Endothelial Function Following Hypoxic Stress

NCT07217249Not ApplicableEnrolling By InvitationPrimary

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

NCT07373821Not ApplicableRecruitingPrimary

Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)

NCT05826353Phase 3CompletedPrimary

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT07024693Phase 2RecruitingPrimary

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07265388RecruitingPrimary

SUCCESS Score Validation in Fuchs Dystrophy

NCT04440280Phase 2RecruitingPrimary

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT07117071CompletedPrimary

Prevalence of Fuchs Endothelial Corneal Dystrophy in a Population of Dermatology Patients.

NCT05376176Phase 2CompletedPrimary

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT06966167RecruitingPrimary

Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts

NCT06969586Enrolling By InvitationPrimary

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

NCT04894110Phase 1Completed

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

NCT06859411RecruitingPrimary

Prognosis of Posterior Lamellar Keratoplasty, an Observational Cohort Study

NCT04250207Phase 2CompletedPrimary

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04520321Phase 1Completed

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT03974230CompletedPrimary

Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France.

NCT05531760CompletedPrimary

Predictive Factors of Graft Detachment Following Dmek

Scroll to load more

Research Network

Activity Timeline